Manuela Ye

ORCID: 0000-0001-7839-9734
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neurofibromatosis and Schwannoma Cases
  • Sarcoma Diagnosis and Treatment
  • Soft tissue tumor case studies
  • Neuroblastoma Research and Treatments
  • Physiological and biochemical adaptations
  • Mitochondrial Function and Pathology
  • Hippo pathway signaling and YAP/TAZ
  • Aquaculture Nutrition and Growth

Institut Cochin
2023-2024

Université Paris Cité
2023-2024

Inserm
2023-2024

Centre National de la Recherche Scientifique
2023-2024

Neurofibromatosis type 1 (NF1) is characterized by the highly variable and unpredictable development of benign peripheral nerve sheath tumours: cutaneous (cNFs), subcutaneous (scNFs) plexiform (pNFs) neurofibromas.

10.1093/bjd/ljad390 article EN British Journal of Dermatology 2023-10-12

Neurofibromatosis type 1 (NF1) is a genetic disorder caused by loss-of-function variants in the tumor-suppressor NF1. About 4-11% of NF1 patients have locus complete deletion resulting from non-allelic homologous recombination between low copy repeats. Co-deleted genes probably account for more severe phenotype observed NF1-deleted patients. This genotype-phenotype correlation highlights need detailed molecular description. We designed digital droplet PCR (ddPCR) set along to delimitate...

10.1016/j.jmoldx.2023.11.005 article EN cc-by Journal of Molecular Diagnostics 2023-11-25

Abstract About 5–10% of neurofibromatosis type 1 (NF1) patients exhibit large genomic germline deletions that remove the NF1 gene and its flanking regions. The most frequent deletion is 1.4 Mb, resulting from homologous recombination between two low copy repeats. This “type-1” associated with a severe clinical phenotype in patients, several phenotypic manifestations including learning disability, much earlier development cutaneous neurofibromas, an increased tumour risk, cardiovascular...

10.1186/s12920-024-01843-5 article EN cc-by BMC Medical Genomics 2024-03-06

<title>Abstract</title> Background The Seahorse XF Analyzer developed by Agilent has revolutionized measurement of the oxidative metabolism cells. Most these measurements use Cell Mito Stress Test, which estimates, among other parameters, maximal cellular oxygen consumption rate (OCRmax) after respiration is stimulated with an uncoupler. This method drawback, however, that OCRmax made full inhibition ATP production mitochondrial phosphorylation (OXPHOS). Moreover, within this protocol only...

10.21203/rs.3.rs-5274954/v1 preprint EN cc-by Research Square (Research Square) 2024-12-11
Coming Soon ...